References

  1. Johnson, D.H., et al., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 2004.22(11): p. 2184-91.
  2. Scagliotti, G.V., et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008.26(21): p. 3543-51.
  3. Travis, W.D., E. Brambilla, and G.J. Riely,New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.J Clin Oncol, 2013.31(8): p. 992-1001.
  4. Sequist, L.V., et al.,Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist, 2007.12(1): p. 90-8.
  5. Sequist, L.V., et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol, 2013.31(27): p. 3327-34.
  6. Paez, J.G., et al.,EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science, 2004.304(5676): p. 1497-500.
  7. Kwak, E.L., et al.,Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med, 2010.363(18): p. 1693-703.
  8. Shaw, A.T., et al.,Ceritinib in ALK-rearranged non-small-cell lung cancer.N Engl J Med, 2014.370(13): p. 1189-97.
  9. Bergethon, K., et al.,ROS1 rearrangements define a unique molecular class of lung cancers.J Clin Oncol, 2012.30(8): p. 863-70.
  10. Mok, T.S., et al.,Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med, 2009.361(10): p. 947-57.
  11. Fukuoka, M., et al., Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011.29(21): p. 2866-74.
  12. Mitsudomi, T., et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010.11(2): p. 121-8.
  13. Inoue, A., et al., Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol, 2013.24(1): p. 54-9.
  14. Maemondo, M., et al.,Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med, 2010.362(25): p. 2380-8.
  15. Rosell, R., et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012.13(3): p. 239-46.
  16. Zhou, C., et al., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011.12(8): p. 735-42.
  17. Wu, Y.L., et al., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014.15(2): p. 213-22.
  18. Bria, E., et al., Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol, 2011.22(10): p. 2277-85.
  19. Lee, C.K., et al.,Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.J Natl Cancer Inst, 2013.105(9): p. 595-605.
  20. Handorf, E.A., et al., Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung.J Oncol Pract, 2012.8(5): p. 267-74.
  21. de Lima Lopes, G., Jr., et al., Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer, 2012.118(4): p. 1032-9.
  22. Brown, T., et al.,Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.Health Technol Assess, 2010.14(Suppl. 2): p. 71-9.
  23. Shaw, A.T., et al.,Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med, 2013.368(25): p. 2385-94.
  24. Djalalov, S., et al., Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol, 2014.32(10): p. 1012-9.
  25. Group, N.M.-A.C., Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol, 2008.26(28): p. 4617-25.
  26. Schiller, J.H., et al.,Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med, 2002.346(2): p. 92-8.
  27. Sandler, A., et al.,Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med, 2006.355(24): p. 2542-50.
  28. Soria, J.C., et al., Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol, 2013.24(1): p. 20-30.
  29. Pirker, R., et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.Lancet, 2009.373(9674): p. 1525-31.
  30. Lynch, T.J., et al., Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol, 2010.28(6): p. 911-7.
  31. Brown, T., et al., Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess, 2013.17(31): p. 1-278.
  32. Goulart, B. and S. Ramsey, A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health, 2011.14(6): p. 836-45.
  33. Paz-Ares, L., et al., Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol, 2012.13(3): p. 247-55.
  34. Ciuleanu, T., et al., Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 2009.374(9699): p. 1432-40.
  35. Paz-Ares, L.G., et al., PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol, 2013.31(23): p. 2895-902.
  36. Klein, R., et al.,Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.J Thorac Oncol, 2010.5(8): p. 1263-72.
  37. Greenhalgh, J., et al.,Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.Health Technol Assess, 2010.14(Suppl. 2): p. 33-9.
  38. Fossella, F.V., et al., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 2000.18(12): p. 2354-62.
  39. Shepherd, F.A., et al., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000.18(10): p. 2095-103.
  40. Hanna, N., et al., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.J Clin Oncol, 2004.22(9): p. 1589-97.
  41. Scagliotti, G., et al.,The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.Oncologist, 2009.14(3): p. 253-63.
  42. Vergnenegre, A., et al., Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thorac Oncol, 2011.6(1): p. 161-8.
  43. Shepherd, F.A., et al.,Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med, 2005.353(2): p. 123-32.